<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In response to DNA damage, the cell cycle checkpoint kinase 2 (CHEK2) may phosphorylate p53, Cdc25A and Cdc25C, and regulate BRCA1 function, leading to cell cycle arrest and DNA repair </plain></SENT>
<SENT sid="1" pm="."><plain>The truncating germline mutation CHEK2(*)1100delC abrogates kinase activity and confers low-penetrance susceptibility to <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We found CHEK2(*)1100delC in 0.5% of 190 oesophageal <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo> and in 1.5% of 196 oesophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, we observed the mutation in 3.0% of 99 Barrett's <z:mpath ids='MPATH_160'>metaplasias</z:mpath> and 1.5% of 66 dysplastic Barrett's epithelia, both known precursor lesions of oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Since CHEK2(*)1100delC mutation frequencies did not significantly differ among oesophageal <z:hpo ids='HP_0002860'>squamous cell carcinomas</z:hpo>, <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and (dysplastic) Barrett's epithelia, as compared to healthy individuals, we conclude that the CHEK2(*)1100delC mutation has no major contribution in oesophageal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>